



Showkat Wani <assistantlibrarian@nitsri.net>

Fwd: ScienceDirect Trial Subscription Activation Letter - Trial Number #1-21440422086

1 message

Asmat Ali <deputylibrarian@nitsri.ac.in>
To: Showkat Wani <assistantlibrarian@nitsri.net>

Sat, Aug 20, 2022 at 2:57 AM

FORWARDED

Regards,**Mrs. Asmat Ali.****(Deputy Librarian)**

National Institute of Technology, Srinagar.

----- Forwarded message -----

From: <activation@elsevier.com>

Date: Mon, Sep 5, 2022 at 10:48 PM

Subject: ScienceDirect Trial Subscription Activation Letter - Trial Number #1-21440422086

To: <deputylibrarian@nitsri.ac.in>

Cc: <f.siddiqui@elsevier.com>

Dear Customer,

We are pleased to provide you and your users with the information you need to successfully trial ScienceDirect at **National Institute of Technology Srinagar**.Your trial start date: **05 September 2022**Your trial end date: **04 November 2022**This limited trial access provided to your organization is for product testing purposes only and will be subject to the terms set forth in the Elsevier terms and conditions, including but not limited to the usage restrictions and limitations of liability set forth therein. <https://www.elsevier.com/legal/elsevier-website-terms-and-conditions>**Getting Started:**Please check your trial access by going to the following URL; www.sciencedirect.com

Title
Business, Management and Accounting
Computer Science

Mathematics

Access is provided to you via:

Your access method: Access has been set up via existing access method. Please continue using the existing IP range (or) user names and passwords, Open Athens or Shibboleth authentication.

To access tools and resources to help you get the most out of ScienceDirect, please visit our Learn & Support page: <http://www.elsevier.com/solutions/sciencedirect/support>

Keep up to date:

Here are a few ways to learn the latest about ScienceDirect:

- Subscribe to our ongoing ScienceDirect Newsletter [here](#) [Embed link: https://communications.elsevier.com/webApp/els_doubleOptInWA?do=0&srv=els_science_direct&sid=68&uif=0&uvis=3]
- Follow [@sciencedirect](#) on Twitter

Once again, we thank you for your purchase and appreciate the opportunity to be of service to you and your users.

The ScienceDirect Team

Achieve more with ScienceDirect

ScienceDirect is Elsevier's leading information solution for researchers. It combines authoritative, full-text scientific, technical, and health content with smart, intuitive functionality so that your users can stay informed in their field, and work more effectively and efficiently.

Help and contacting us

To get in contact with us, please visit our [support center overview page](#). Here you will find links to all our products online support, where you can contact us and find answers to frequently asked questions.

Please do not reply to this message as this is an automated email which cannot receive responses. Kindly contact us via our [support center](#)

Disclaimer: This email is for use by the intended recipient and contains information that may be confidential. If you are not the intended recipient, please notify the sender by return email and delete this email from your inbox. Any unauthorized use or distribution of this email, in whole or in part, is strictly prohibited and may be unlawful.

[THREAD ID:1-9UT98VO]

This electronic mail message and any attached files are confidential.

The information is exclusively for the use of the individual or entity intended as the recipient. If you are not the intended recipient, any use, copying, printing, reviewing, retention, disclosure, distribution or forwarding of the message or any attached file is not authorized and is strictly prohibited. If you have received this electronic mail message in error, please advise the sender by reply electronic mail immediately and permanently delete the original transmission, any attachments and any copies of this message from your computer system.